Physician profile
Michelle E Mullins
NPI 1548893605
$3,114.20
in general payments reported to CMS, 2019-2025
24 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $662 · 2022: $709 · 2023: $841 · 2024: $534 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267 · Education: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.94 |
| Education | $475.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $519.13 | 2021-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $374.19 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $340.14 | 2021-2024 | Xarelto |
| Amgen INC. | $286.98 | 2021-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $221.80 | 2021-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.38 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $163.98 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $154.65 | 2022-2024 | |
| Boston Scientific Corporation | $134.50 | 2023-2024 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $132.45 | 2021-2024 | |
| Abiomed | $126.80 | 2022-2023 | Impella |
| Actelion Pharmaceuticals US, INC. | $115.02 | 2022-2025 | Uptravi, Opsumit |
| Lexicon Pharmaceuticals, INC. | $59.21 | 2024 | |
| Merck Sharp & Dohme LLC | $53.80 | 2024-2025 | Verquvo |
| Philips North America LLC | $47.23 | 2023-2024 | (5044) Mcot, (Ck4) Mcot |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.24 | 2022 | |
| Medtronic, INC. | $30.71 | 2022 | |
| Cardiovascular Systems INC. | $25.80 | 2021 | |
| Ucb, INC. | $23.98 | 2025 | Briviact |
| Ge Healthcare | $23.88 | 2025 | |
| Chiesi USA, INC. | $18.16 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $15.79 | 2024 | Arcalyst |
| Novo Nordisk INC | $13.96 | 2023 | Ozempic |
| Impulse Dynamics (USA) INC. | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.